Cargando…
Corticosteroid Treatment Prevents Lipopolysaccharide-Induced Increase of ACE2 and Reduces Fibrin Degradation Products in Bronchoalveolar Lavage Fluid
The assessment of systemic corticosteroid effects on intrapulmonary disease biomarkers is challenging. This retrospective evaluation of a human endotoxemia model quantified ACE2 and fibrin degradation product (FDP) concentrations in bronchoalveolar lavage fluid (BALF) samples from a randomized, doub...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924661/ https://www.ncbi.nlm.nih.gov/pubmed/35308535 http://dx.doi.org/10.3389/fmed.2022.856891 |
_version_ | 1784669908420788224 |
---|---|
author | Reindl-Schwaighofer, Roman Eskandary, Farsad Bartko, Johann Heinzel, Andreas Jilma, Bernd Hecking, Manfred Schoergenhofer, Christian |
author_facet | Reindl-Schwaighofer, Roman Eskandary, Farsad Bartko, Johann Heinzel, Andreas Jilma, Bernd Hecking, Manfred Schoergenhofer, Christian |
author_sort | Reindl-Schwaighofer, Roman |
collection | PubMed |
description | The assessment of systemic corticosteroid effects on intrapulmonary disease biomarkers is challenging. This retrospective evaluation of a human endotoxemia model quantified ACE2 and fibrin degradation product (FDP) concentrations in bronchoalveolar lavage fluid (BALF) samples from a randomized, double-blind, placebo-controlled study (NCT01714427). Twenty-four healthy volunteers received either 2 × 40 mg intravenous dexamethasone or placebo. These doses were administered 12 h apart prior to bronchoscopy-guided intrabronchial lipopolysaccharide (LPS) stimulation (control: saline into the contralateral lung segment). We quantified ACE2 concentration, the Angiotensin-II-to-Angiotensin-1-7 conversion rate as well as FDP in BALF 6 h after LPS instillation. In placebo-treated subjects, LPS instillation increased ACE2 concentrations compared to unstimulated lung segments [1,481 (IQR: 736–1,965) vs. 546 (413–988) pg/mL; p = 0.016]. Dexamethasone abolished the increase in ACE2 concentrations (p=0.13). Accordingly, LPS instillation increased the Angiotensin-II-to-Angiotensin-1-7 conversion capacity significantly in the placebo cohort, indicating increased enzymatic activity (p = 0.012). FDP increased following LPS-instillation [8.9 (2.7–12.2) vs. 6.6 (0.9–9.6) ng/mL, p = 0.025] in the placebo group, while dexamethasone caused a shut-down of fibrinolysis in both lung segments. LPS instillation increased ACE2 concentration, its enzymatic activity and FDP, which was mitigated by systemic dexamethasone treatment. Our results strengthen previously published findings regarding the efficiency of corticosteroids for the treatment of COVID-19-induced acute lung injury. |
format | Online Article Text |
id | pubmed-8924661 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89246612022-03-17 Corticosteroid Treatment Prevents Lipopolysaccharide-Induced Increase of ACE2 and Reduces Fibrin Degradation Products in Bronchoalveolar Lavage Fluid Reindl-Schwaighofer, Roman Eskandary, Farsad Bartko, Johann Heinzel, Andreas Jilma, Bernd Hecking, Manfred Schoergenhofer, Christian Front Med (Lausanne) Medicine The assessment of systemic corticosteroid effects on intrapulmonary disease biomarkers is challenging. This retrospective evaluation of a human endotoxemia model quantified ACE2 and fibrin degradation product (FDP) concentrations in bronchoalveolar lavage fluid (BALF) samples from a randomized, double-blind, placebo-controlled study (NCT01714427). Twenty-four healthy volunteers received either 2 × 40 mg intravenous dexamethasone or placebo. These doses were administered 12 h apart prior to bronchoscopy-guided intrabronchial lipopolysaccharide (LPS) stimulation (control: saline into the contralateral lung segment). We quantified ACE2 concentration, the Angiotensin-II-to-Angiotensin-1-7 conversion rate as well as FDP in BALF 6 h after LPS instillation. In placebo-treated subjects, LPS instillation increased ACE2 concentrations compared to unstimulated lung segments [1,481 (IQR: 736–1,965) vs. 546 (413–988) pg/mL; p = 0.016]. Dexamethasone abolished the increase in ACE2 concentrations (p=0.13). Accordingly, LPS instillation increased the Angiotensin-II-to-Angiotensin-1-7 conversion capacity significantly in the placebo cohort, indicating increased enzymatic activity (p = 0.012). FDP increased following LPS-instillation [8.9 (2.7–12.2) vs. 6.6 (0.9–9.6) ng/mL, p = 0.025] in the placebo group, while dexamethasone caused a shut-down of fibrinolysis in both lung segments. LPS instillation increased ACE2 concentration, its enzymatic activity and FDP, which was mitigated by systemic dexamethasone treatment. Our results strengthen previously published findings regarding the efficiency of corticosteroids for the treatment of COVID-19-induced acute lung injury. Frontiers Media S.A. 2022-03-02 /pmc/articles/PMC8924661/ /pubmed/35308535 http://dx.doi.org/10.3389/fmed.2022.856891 Text en Copyright © 2022 Reindl-Schwaighofer, Eskandary, Bartko, Heinzel, Jilma, Hecking and Schoergenhofer. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Reindl-Schwaighofer, Roman Eskandary, Farsad Bartko, Johann Heinzel, Andreas Jilma, Bernd Hecking, Manfred Schoergenhofer, Christian Corticosteroid Treatment Prevents Lipopolysaccharide-Induced Increase of ACE2 and Reduces Fibrin Degradation Products in Bronchoalveolar Lavage Fluid |
title | Corticosteroid Treatment Prevents Lipopolysaccharide-Induced Increase of ACE2 and Reduces Fibrin Degradation Products in Bronchoalveolar Lavage Fluid |
title_full | Corticosteroid Treatment Prevents Lipopolysaccharide-Induced Increase of ACE2 and Reduces Fibrin Degradation Products in Bronchoalveolar Lavage Fluid |
title_fullStr | Corticosteroid Treatment Prevents Lipopolysaccharide-Induced Increase of ACE2 and Reduces Fibrin Degradation Products in Bronchoalveolar Lavage Fluid |
title_full_unstemmed | Corticosteroid Treatment Prevents Lipopolysaccharide-Induced Increase of ACE2 and Reduces Fibrin Degradation Products in Bronchoalveolar Lavage Fluid |
title_short | Corticosteroid Treatment Prevents Lipopolysaccharide-Induced Increase of ACE2 and Reduces Fibrin Degradation Products in Bronchoalveolar Lavage Fluid |
title_sort | corticosteroid treatment prevents lipopolysaccharide-induced increase of ace2 and reduces fibrin degradation products in bronchoalveolar lavage fluid |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924661/ https://www.ncbi.nlm.nih.gov/pubmed/35308535 http://dx.doi.org/10.3389/fmed.2022.856891 |
work_keys_str_mv | AT reindlschwaighoferroman corticosteroidtreatmentpreventslipopolysaccharideinducedincreaseoface2andreducesfibrindegradationproductsinbronchoalveolarlavagefluid AT eskandaryfarsad corticosteroidtreatmentpreventslipopolysaccharideinducedincreaseoface2andreducesfibrindegradationproductsinbronchoalveolarlavagefluid AT bartkojohann corticosteroidtreatmentpreventslipopolysaccharideinducedincreaseoface2andreducesfibrindegradationproductsinbronchoalveolarlavagefluid AT heinzelandreas corticosteroidtreatmentpreventslipopolysaccharideinducedincreaseoface2andreducesfibrindegradationproductsinbronchoalveolarlavagefluid AT jilmabernd corticosteroidtreatmentpreventslipopolysaccharideinducedincreaseoface2andreducesfibrindegradationproductsinbronchoalveolarlavagefluid AT heckingmanfred corticosteroidtreatmentpreventslipopolysaccharideinducedincreaseoface2andreducesfibrindegradationproductsinbronchoalveolarlavagefluid AT schoergenhoferchristian corticosteroidtreatmentpreventslipopolysaccharideinducedincreaseoface2andreducesfibrindegradationproductsinbronchoalveolarlavagefluid |